Inactive Instrument

Lotus Pharmaceuticals, Inc. Share Price Other OTC

LTUS

US5457152032

Valuation: Lotus Pharmaceuticals, Inc.

Market Cap	9.74M 8.51M 7.82M 7.29M 13.83M 927M 14.04M 93.39M 36.51M 455M 36.54M 35.75M 1.57B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.58M 11.56M 10.77M 20.43M 1.37B 20.74M 138M 53.93M 673M 53.98M 52.82M 2.32B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

* Estimated data More valuation ratios

Latest news : Lotus Pharmaceuticals, Inc.

31/07/23	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/11/21	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
28/09/21	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
16/05/12	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
19/04/12	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

More news

Press Releases: Lotus Pharmaceuticals, Inc.

12-30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
06/10/25	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
12/08/25	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
21/02/25	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
08/11/24	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

More press releases

Managers and Directors: Lotus Pharmaceuticals, Inc.

Manager	Title	Age	Since
Georgene Rivers CEO	Chief Executive Officer	-	-

Director	Title	Age	Since
Georgene Rivers BRD	Director/Board Member	-	-

More insiders

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LOTUS PHARMACEUTICALS, INC.	+41.51%	-18.92%	-	-	8.2M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+1.81%	+2.25%	+13.63%	+81.62%	48B
OTSUKA HOLDINGS CO., LTD.	-2.54%	+3.72%	+66.86%	+116.52%	36.89B
CIPLA LIMITED	+0.15%	+1.26%	-3.64%	+44.11%	12.37B
ZYDUS LIFESCIENCES LIMITED	+3.71%	+3.56%	+13.95%	+98.68%	11.95B
KRKA, D. D.	+0.39%	+0.58%	+32.90%	+120.94%	9.01B
GEDEON RICHTER	+0.66%	-0.57%	+19.74%	+46.69%	7.2B
ONO PHARMACEUTICAL CO., LTD.	+0.71%	+1.75%	+52.67%	-6.28%	7.05B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+9.99%	+32.94%	-15.50%	+25.64%	6.58B
GLENMARK PHARMACEUTICALS LIMITED	+0.68%	+2.63%	+20.79%	+240.34%	6.55B
Average	+5.71%	+4.24%	+22.38%	+85.36%	16.18B
Weighted average by Cap.	+0.85%	+3.35%	+28.07%	+89.74%

	2009	2010
Net sales	57.82M 50.56M 46.47M 43.31M 82.15M 5.5B 83.37M 555M 217M 2.71B 217M 212M 9.33B	72.7M 63.57M 58.43M 54.45M 103M 6.92B 105M 697M 273M 3.4B 273M 267M 11.73B
Net income	16.43M 14.37M 13.21M 12.31M 23.34M 1.56B 23.69M 158M 61.62M 769M 61.68M 60.35M 2.65B	14.42M 12.61M 11.59M 10.8M 20.49M 1.37B 20.8M 138M 54.09M 675M 54.14M 52.98M 2.33B
Net Debt	5.29 4.63 4.25 3.96 7.52 503.97 7.63 50.78 19.85 247.66 19.87 19.44 854.37	4.65 4.06 3.73 3.48 6.6 442.37 6.7 44.57 17.42 217.39 17.44 17.07 749.93

Lotus Pharmaceuticals, Inc. Share Price Other OTC

Stocks

LTUS

US5457152032

Pharmaceuticals

Valuation: Lotus Pharmaceuticals, Inc.

Latest news : Lotus Pharmaceuticals, Inc.

Press Releases: Lotus Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Lotus Pharmaceuticals, Inc.

Generic Pharmaceuticals

Financials

Company Profile